LEADS BIOLABS-B (09887) announced that the American Society of Hematology (ASH) has released the abstract review results for its 67th Annual Meeting. The company's two innovative drugs have achieved successful inclusion with a total of five research abstracts, comprising one oral presentation, three poster presentations, and one online publication. The company has consistently presented innovative drug development achievements at international platforms including ASH and the American Society of Clinical Oncology (ASCO) for multiple consecutive years. The concentrated selection of multiple research achievements for the 67th ASH Annual Meeting represents high recognition from the international academic community for the company's scientific research and innovation capabilities.